1.

Organ donation in Belgium 2011: the highest donation rate ever

2.

Organ donation in Belgium 2011: the highest donation rate ever

3.

Organ donation in Belgium 2011: the highest donation rate ever

4.

Organ donation in Belgium 2011: the highest donation rate ever

5.

Organ donation in Belgium 2011: the highest donation rate ever

6.

Organ donation in Belgium 2011: the highest donation rate ever

7.

Organ donation in Belgium 2011: the highest donation rate ever

8.

Organ donation in Belgium 2011: the highest donation rate ever

9.

Organ donation in Belgium 2011: the highest donation rate ever

1.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

2.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

3.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

4.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

5.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

6.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

7.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

8.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

1.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

2.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

3.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

4.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

5.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

6.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

7.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

8.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

9.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

1.

Female representation in orthopedic surgery: where do we stand in Belgium ?

2.

Female representation in orthopedic surgery: where do we stand in Belgium ?

3.

Female representation in orthopedic surgery: where do we stand in Belgium ?

4.

Female representation in orthopedic surgery: where do we stand in Belgium ?

5.

Female representation in orthopedic surgery: where do we stand in Belgium ?

6.

Female representation in orthopedic surgery: where do we stand in Belgium ?

7.

Female representation in orthopedic surgery: where do we stand in Belgium ?

8.

Female representation in orthopedic surgery: where do we stand in Belgium ?

9.

Female representation in orthopedic surgery: where do we stand in Belgium ?

1.

Obesity: trend in inequality.

2.

Obesity: trend in inequality.

3.

Obesity: trend in inequality.

4.

Obesity: trend in inequality.

5.

Obesity: trend in inequality.

1.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

2.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

3.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

4.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

5.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

6.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

7.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

8.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

9.

Alcohol consumption changes following COVID-19 lockdown among French-speaking Belgian individuals at risk for alcohol use disorder.

1.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

2.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

3.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

4.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

5.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

6.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

7.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

8.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

9.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

1.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

2.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

3.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

4.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

5.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

6.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

7.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

8.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

9.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

1.

Deconstructing trait anxiety: a network perspective.

2.

Deconstructing trait anxiety: a network perspective.

3.

Deconstructing trait anxiety: a network perspective.

4.

Deconstructing trait anxiety: a network perspective.

5.

Deconstructing trait anxiety: a network perspective.

1.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

2.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

3.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

4.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

5.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

6.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

7.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

8.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

9.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.